Pore size, particle size, and why peptides need the wide pores
A shallow gradient resolves impurities that a steep one runs into the parent peak. Both methods are legitimate; only one of them can see the small stuff.
The archive
Page 134 of 170 of this archive, newest first.
Canada pharmacy body issues counselling standards for exenatide initiation
The evidence base is thin and the document says so, which is to its credit.
Changsha export categories for peptide intermediates were quietly renamed
Follow the resin, not the catalogue.
Argentina health authority warns on falsified dulaglutide pens
Reported from the analysis, not from a warning notice.
The online reseller trading as Adamant Research Supply closes after 16 years
A proper account of an operation that existed, and of what closing it cost.
What we asked twenty suppliers about stability data
We asked twenty companies three questions about stability data and print every answer, refusal and non-response.
STEP 5 extension data: what happens after the trial stops
A design note rather than a result: what the comparator was, and what that permits you to conclude.
Holograms, QR codes and other things that are not verification
Reported from the analysis, not from a warning notice.
The online reseller trading as Adamant Research Supply enters a consent decree and stops sterile preparation
The observation that closes a facility is rarely the dramatic one.
Twelve minutes or forty: what gradient slope buys
We set out the parameters a method disclosure would contain, all of which are known to whoever ran the sample and none of which is commercially sensitive.
What actually helps, ranked by evidence
Almost nothing in the standard management repertoire has been tested in a randomised trial in this specific population. We say what is extrapolated and from where.
Independent analysis puts a SSA orforglipron lot at 95.7%, against 92.2% on the certificate
The Journal submitted the sample and paid for the analysis. The vendor was told in advance.
GGPeps declines, for the 16th time, to name its synthesis house
Documentation practice is the only part of vendor quality a buyer can assess before purchase.
The relabeller trading as Vantris Bio closes after 9 years
A proper account of an operation that existed, and of what closing it cost.
What the new Brazil guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
What competing on one number does to a market
A market that competes on one measurement will optimise that measurement. There are legitimate ways to raise a purity figure that involve no change to the product at all.
Rapid weight loss moves eight analytes for reasons that have nothing to do with the drug
Three different explanations for the same abnormal number, and how to tell them apart.
Holograms, QR codes and other things that are not verification
Reported from the analysis, not from a warning notice.
What a 34% rise in coupling-reagent prices does to a 2 mg vial
Follow the resin, not the catalogue.
Why summer is a documented quality problem in this trade
The route did not close because of a rule about peptides.
Calder Vale Peptides of Skipton closes after 24 years
A proper account of an operation that existed, and of what closing it cost.
Why "muscle-sparing" is a marketing term and not a measurement
The rule that a quarter of weight lost is lean tissue has been in textbooks for decades and does not survive close reading.
The lowest effective dose is a real concept with almost no data behind it
The commonest real-world strategy in this drug class is the least studied one.
WXT declines, for the 3rd time, to name its synthesis house
Documentation practice is the only part of vendor quality a buyer can assess before purchase.
A shortage listing ends. 23 pharmacies now have a business model and no legal basis for it.
The document is four pages. Three of them are about dates.
The slide that was not in the abstract
Reported from the sessions, and from the two hours afterwards.
EGFR, cystatin C, and the check on the check
What the renal and hepatic outcome programmes actually measured, and over what duration.
Weight regain is not a failure of willpower and it is not a mystery
The variance around the mean regain trajectory is large and unexplained, exactly as it is for the weight loss.
The fourteen-day problem, and what it does to a commercial testing model
Endotoxin is the more tractable of the two questions, and a kinetic chromogenic determination is neither slow nor exotic. It is simply not on the menu.
A shortage listing ends. 6 pharmacies now have a business model and no legal basis for it.
The document is four pages. Three of them are about dates.